Skip to main content
Premium Trial:

Request an Annual Quote

AnVil, Genomics Collaborative to Build New CV Products

NEW YORK, Nov. 5-AnVil and Genomics Collaborative will work together to develop new products and resources for the life sciences market, AnVil said today.

 

Using its informatics and data visualization capabilities, AnVil will analyze cardiovascular clinical data from GCI's database. The two companies will build predictive and analytic models for coronary artery disease, myocardial infarction, hyperlipidemia and hypertension.

 

From this collaboration, the companies hope to develop products that will be useful to pharmaceutical and biotech companies in cardiovascular drug development. They will jointly develop a marketing and business plan.

 

AnVil is a data management and visualization company based in Burlington, Mass.

 

The two companies struck a deal to develop drugs for rheumatoid arthritis in April 2002.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.